April 18, 2017 06:27 AM EDT

Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

John Carroll

Editor & Founder

Looking to leapfrog some intense competition to field new drugs for NASH and fatty liver disease, pharma giant Novartis has struck a deal to partner …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

A look at biotech's year of the megaround

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Neumora's major depression drug flunks first of three Phase 3 trials

No­var­tis joins forces with Al­ler­gan, push­ing a NASH com­bo in­to late-stage de­vel­op­ment

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

A look at biotech's year of the megaround

FDA ad­comm to re­view No­var­tis' Fab­hal­ta in ul­tra-rare kid­ney dis­ease

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Novartis joins forces with Allergan, pushing a NASH combo into late-stage development

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

FDA adcomm to review Novartis' Fabhalta in ultra-rare kidney disease

Neumora's major depression drug flunks first of three Phase 3 trials